Cost-Effectiveness of Alzheimer’s Drugs: NICE’s New Threshold Explained
The 2 medications, lecanemab and donanemab will be reassessed for NHS use following successful appeals from their manufacturers. Last year, the National Institute for Health and Care Excellence (NICE) concluded that lecanemab and donanemab should not be funded by the NHS for patients with mild cognitive impairment or early-stage Alzheimer’s disease. NICE had determined that the treatments were not a cost-effective use of limited healthcare […]
Cost-Effectiveness of Alzheimer’s Drugs: NICE’s New Threshold Explained Read More »




